Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGTA-145 for Stem Cell Mobilization in SCD
NCT05445128Phase 2Terminated
- Sponsor
- Ensoma
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of MGTA-145 in sickle cell disease (SCD), sponsored by Ensoma. Started Jun 2022; status: terminated.
02
Drugs
MGTA-145
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05445128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445128.